profit from every $100 of sales.
$0$100
Oaktree Acquisition Corp. III Life Sciences
$10.70-0.00% today
+0.9% in 1 year
1-year low $10.541-year high $10.93
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
You pay $19.45 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Oaktree Acquisition Corp. III Life Sciences vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Oaktree Acquisition Corp. III Life Sciences | 19.5× · No profit yet | ||
 Churchill Capital Corp X | No profit yet | ||
 Drugs Made In America Acquisition II | 155.9× · No profit yet | ||
 Unusual Machines | No profit yet | ||
 Bain Capital GSS Investment Cor | No profit yet |
AI analysis
An AI analyst reads Oaktree Acquisition Corp. III Life Sciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2025 |
|---|---|
| 0 | |
| – | |
| -1 | |
| -1 | |
| 7 | |
| 0.30 | |
| – | |
| – | |
| – |
Balance sheet
| In millions of USD | 2025 |
|---|---|
| Total assets | 203 |
| Cash | 1 |
| Total debt | 0 |
| Total liabilities | 8 |
| 195 | |
| 25 | |
| -0.5% | |
| 3.7% |
Cash flow
| In millions of USD | 2025 |
|---|---|
| -0 | |
| – | |
| -0 | |
| Dividends paid | – |
| – | |
| – |
Valuation
- 19.5×
- –
- 0.04
- 1.0×
- –
- –
- –
- -0.3%
- 5.1%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -0.6%
- 1.9%
- 3.6%
- 3.4%
- -0.6%
- –
Growth
- –
- +453.5%
- −235,698.3%
- –
- −21.9%
Financial health
- 1.0×
- 0.00
- 0.0%
- –
- 0.87
- 0.87
- 0.00
How it ranks in Financial Services
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 9%of 827
Bottom 6%of 709
Bottom 29%of 876
Bottom 19%of 926
News
Oaktree's Howard Marks backs quieter Fed, calls for AI jobs task forceSeeking Alpha · Sep 20, 2026TORM announces closing of 9M share secondary offering by Oaktree affiliateSeeking Alpha · Sep 17, 2026The newest story we have is from Sep 20, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
37No pass
Benjamin Graham
70Pass
Philip Fisher
41No pass
Peter Lynch
60Pass
Joel Greenblatt
11No pass
Charlie Munger
28No pass
Terry Smith
22No pass
Questions about Oaktree Acquisition Corp. III Life Sciences
Is Oaktree Acquisition Corp. III Life Sciences a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Oaktree Acquisition Corp. III Life Sciences AI analysis
What does Oaktree Acquisition Corp. III Life Sciences do?
Oaktree Acquisition Corp. III Life Sciences focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It is in Shell Companies.
Does Oaktree Acquisition Corp. III Life Sciences pay a dividend?
No. Oaktree Acquisition Corp. III Life Sciences does not pay a dividend at the moment.
Is Oaktree Acquisition Corp. III Life Sciences stock halal?
Questionable. Oaktree Acquisition Corp. III Life Sciences sits in a grey zone: scholars disagree about its industry. How we check
How has Oaktree Acquisition Corp. III Life Sciences stock done over the past year?
Up 0.9% over the past twelve months, to $10.70. It traded between $10.54 and $10.93 and is 2.1% below its high.
Who are Oaktree Acquisition Corp. III Life Sciences's competitors?
The largest listed companies in the same industry are Churchill Capital Corp X, Drugs Made In America Acquisition II, Unusual Machines and Bain Capital GSS Investment Cor. The peers table on this page compares their profit, growth and price with Oaktree Acquisition Corp. III Life Sciences's.
Prices: daily closes to Nov 6, 2026. Fundamentals: company reports via invest-like data.